| 產品名稱 |
L-NGC-5HT2 |
| 商品貨號 |
B164996 |
| Organism |
Mus musculus, mouse |
| Tissue |
subcutaneous connective tissue; areolar and adipose |
| Cell Type |
fibroblast |
| Product Format |
frozen |
| Morphology |
fibroblast |
| Culture Properties |
adherent |
| Biosafety Level |
1 (SV-40 Transformed African Green Monkey)
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain |
C3H/An |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
This line is a derivative of L-M(TK-) that is stably transfected with the gene for the human type 2 5-hydroxytryptamine (serotonin) receptor (5HT2). |
| Receptor Expression |
5-hydroxytryptamine (serotonin, 5HT2), expressed |
| Comments |
This line is a derivative of L-M(TK-) that is stably transfected with the gene for the human type 2 5-hydroxytryptamine (serotonin) receptor (5HT2). |
| Complete Growth Medium |
Dulbecco's modified Eagle's medium with 4.5g/L glucose, 90%; fetal bovine serum, 10%
|
| Subculturing |
Protocol: Remove medium, add fresh 0.25% trypsin solution for 2 to 5 minutes, remove trypsin and let the culture sit at 37C for 10 to 15 minutes. Add fresh medium, aspirate and dispense into new flasks. Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended Medium Renewal: 2 to 3 times per week |
| Cryopreservation |
Freeze medium: culture medium, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor phase |
| Name of Depositor |
Synaptic Pharmaceutical Corporation |
| Deposited As |
Cercopithecus aethiops |
| U.S. Patent Number |
|
| References |
Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995
|
